Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight and metabolic changes after switching suppressive HIV therapy
2020-000205-89Phase 4Terminated
- Sponsor
- Department of Infectious Diseases, Hvidovre Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dolutegravir, lamivudine, tenofovir disoproxil fumarate and doravirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Department of Infectious Diseases, Hvidovre Hospital. Primary endpoint: Change in body weight >2 kg from baseline to week 48. Started Feb 2020; status: terminated.
02
Drugs
dolutegravirlamivudinetenofovir disoproxil fumaratedoravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-000205-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000205-89.